Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both ...

US biotech Iovance Biotherapeutics is cutting 19% of its workforce due to slower-than-expected launch of its ...

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) ...

A new report in Open Forum Infectious Diseases details the significant increase of the Babesia season in New England since ...

The U.S. government just signed a $1 deal with OpenAI to bring ChatGPT to federal agencies. Here's what it means for AI’s future in government.

The 9th Coast Guard District, or D9 as it is known to the 5,000 people stationed at more than 78 units across five sectors, ...

Replimune (REPL) stock plummets as report suggests FDA’s top regulator of cancer drugs intervened in rejecting its lead asset ...

Stephen Colbert Puts on JD Vance Mask and Says ‘Netflix, Call Me' After CBS Cancels ‘The Late Show': ‘I'm Available in June' ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...

BioAtla, Inc. ( NASDAQ: BCAB) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Eric L. Sievers - Chief Medical Officer Jay M. Short - Co-Founder, CEO & Chairman Richard A. Waldron - Senior ...

In its second-quarter financial filing, Iovance said it was planning to shed 19% of its workforce of more than 630 in order ...

Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the ...